EBS News and Press, Emergent Biosolutions Inc. From 02/24/23

Emergent Biosolutions ( NYSE: EBS ) is scheduled to announce Q4 earnings results on Monday, February 27th, after market close. The consensus EPS Estimate is $0.07 (compared to $4.5 in year ago quarter) and the consensus Revenue Estimate is $291.27M (-59.7% Y/Y). Over the last ...

Summary Emergent BioSolutions has shown a remarkable turnaround since challenging Q3:22 results with a $380 million procurement contract and restructuring plan. Now, a definitive step toward a NARCAN over-the-counter approval. EBS has entered into an agreement to sell its Travel Hea...

If approved by the FDA, NARCAN Nasal Spray will be the first 4 mg naloxone nasal spray switched from prescription status to over-the-counter use GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) --  Today, Emergent BioSolutions Inc. (NYSE:EBS) announced the U.S. Food and Drug Adminis...

A US FDA advisory panel voted unanimously that Emergent BioSolutions' ( NYSE: EBS ) opioid overdose reversal agent Narcan (naloxone) should be made available over the counter. The FDA is slated to make a final decision on the OTC status by March 29. If it gives the go-ahead, Emergent ...

Emergent BioSolutions ( NYSE: EBS ) to sell its travel health business to Bavarian Nordic ( OTCPK:BVNRY ) for $380M, comprising of $270M in upfront cash consideration, up to $30M in sales-based milestones associated with the commercial products and up to $80M in development-based ...

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential future milestone payments. Under ...

GAITHERSBURG, Md., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, February 27, 2023, at 5:00 pm eastern time to discuss the financial results for the fourth quarter of 2022, recent business developments, and financial outlook for fu...

Summary I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought. The CVR helps to bridge the gap between the price the seller wants and the buyer wants to pay. They are always uniquely structu...

Announces Preliminary 2022 Financial Results GAITHERSBURG, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a sharpened strategic focus on protecting and enhancing life through its core businesses, consisting of medical countermeasures (MCM) and commerc...

Emergent BioSolutions ( NYSE: EBS ) on Thursday said it had been awarded a contract valued up to ~$380M to supply skin decontamination lotion kits for use by all branches of the U.S. military. EBS shares gained 11.8% to $13.80 after hours. EBS' Canadian unit will serve as the ...